BillionToOne is a molecular diagnostics company committed to advancing healthcare through precise and accessible diagnostic tests. Utilizing its proprietary QCT molecular counting technology, BillionToOne significantly improves disease detection capabilities using cell-free DNA. Their flagship products include Unity Complete, a non-invasive prenatal screening test that evaluates risk for both common recessive conditions and aneuploidies, and the Northstar liquid biopsy test for oncology, which integrates treatment selection with monitoring. Since its inception, the company has served over 500,000 patients and has experienced rapid growth, achieving a valuation exceeding $1 billion following substantial funding rounds. Headquartered in Menlo Park, California, BillionToOne fosters a diverse and innovative team culture, emphasizing a commitment to quality, collaboration, and impactful healthcare solutions.